Cargando…
MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial
OBJECTIVES: To investigate changes in the Apparent Diffusion Coefficient (ADC) using diffusion-weighted imaging (DWI) in men on active surveillance for prostate cancer taking dutasteride 0.5 mg or placebo. METHODS: We analysed 37 men, randomised to 6 months of daily dutasteride (n = 18) or placebo (...
Autores principales: | Giganti, Francesco, Moore, Caroline M., Robertson, Nicola L., McCartan, Neil, Jameson, Charles, Bott, Simon R. J., Winkler, Mathias, Gambarota, Giulio, Whitcher, Brandon, Castro, Ramiro, Emberton, Mark, Allen, Clare, Kirkham, Alex |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635085/ https://www.ncbi.nlm.nih.gov/pubmed/28523355 http://dx.doi.org/10.1007/s00330-017-4858-0 |
Ejemplares similares
-
Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial
por: Giganti, Francesco, et al.
Publicado: (2021) -
Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study
por: Giganti, Francesco, et al.
Publicado: (2019) -
Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort
por: Giganti, Francesco, et al.
Publicado: (2020) -
Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship
por: Giganti, Francesco, et al.
Publicado: (2022) -
Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)—do we still need contrast media?
por: Huebner, Nicolai Alexander, et al.
Publicado: (2020)